Preparing Australia For Genomic Medicine: A Proposal By The Australian Genomics Health Alliance
Funder
National Health and Medical Research Council
Funding Amount
$25,000,000.00
Summary
The sequencing of the human genome brings the possibility of more accurate identification of the underlying basis of many diseases. This technology has moved so rapidly, however, that clinical access has been limited. In this application, a national alliance of clinicians, researchers, health economists and policymakers will evaluate the case for clinical genomics across inherited disease and cancer, determine how best to deliver this to the patient and train a capable workforce.
Electrophysiologic Phenotyping Of Non Ischaemic Cardiomyopathy To Predict Clinical Outcome
Funder
National Health and Medical Research Council
Funding Amount
$374,676.00
Summary
Non-ischemic cardiomyopathy (NICM) is a common cause of heart failure and sudden death. Currently, the guidelines for the management are generalised and do not differentiate patients at high risk of disease progression and sudden death. This project aims to identify the electrical and structural properties of heart, to predict the clinical course in patients with NICM. Identification of high-risk patients will help allocate resources wisely and enable appropriate patient counselling.
Blood Protein Biomarkers For Frontotemporal Lobar Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$184,305.00
Summary
This project will assess blood proteins as biomarkers for different pathogenic forms of frontotemporal dementia (FTD), one of the major neurodegenerative dementias with a very rapid disease progression (mean survival 3 years). At present, it is not possible to predict which pathological variant is present in any given patient. We plan to develop blood protein biomarker assays capable of diagnosing the pathology in vivo.
Study Of C-KIT Mutations In Familial Gastrointestinal Stromal Tumours, Melanoma And A Novel Form Of Waardenburg Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$68,378.00
Summary
The primary aim of this research project is to study mutations in a cancer causing gene called c-KIT. We seek to identify tumour characteristics which are predictive for the presence of particular types of c-KIT mutations in melanomas and gastrointestinal stromal tumours. The detection of tumours harbouring these mutations will help in the treatment of cancer sufferers because this group of patients have been shown to respond very well to a class of drugs known as tyrosine kinase inhibitors.
SNAC2: A Randomised Trial Of Extending Sentinel Node Based Management To Women With Larger Or Multifocal Breast Cancers
Funder
National Health and Medical Research Council
Funding Amount
$1,266,430.00
Summary
SNAC2 extends the work begun in SNAC1, which recruited 1,088 women over 4 years. SNAC1 will determine if sentinel node biopsy causes less arm problems than axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours. SNAC2 is needed to determine whether the smaller operation gives cure rates as good as axillary clearance. If it does, then it will become standard practice.
Preclinical Evaluation Of F-18 Fluoroethyltriazolyl PEGstilbenes As Potential PET Imaging Agents For Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$673,238.00
Summary
Alzheimer's disease (AD) is the most common form of dementia and is becoming am ever increasing burden to the health system due to the aging of our population. Amyloid plaques are considered the hallmark of AD and a technique for their detection in vivo would be a breakthrough, not only for the diagnosis of AD but also for the development of drugs against AD. Nuclear medicine can image tissue function non-invasively. This project aims to develop new imaging agents to improve diagnosis of AD.
Molecular And Clinico-pathological Investigation Of Congenital Myopathies
Funder
National Health and Medical Research Council
Funding Amount
$743,290.00
Summary
Congenital myopathies are inherited disorders causing muscle weakness from birth. Some types lead to early death of the affected child, while others are compatible with life to adulthood. Like any disease of childhood, the congenital myopathies cause considerable trauma to the families concerned. Couples at risk of having another affected child frequently wait for prenatal diagnosis to become available for their particular disease before attempting to have further children. However, prenatal dia ....Congenital myopathies are inherited disorders causing muscle weakness from birth. Some types lead to early death of the affected child, while others are compatible with life to adulthood. Like any disease of childhood, the congenital myopathies cause considerable trauma to the families concerned. Couples at risk of having another affected child frequently wait for prenatal diagnosis to become available for their particular disease before attempting to have further children. However, prenatal diagnosis is only possible once the gene causing a disorder and the mutation in an individual family are identified. In the past, the Laboratories collaborating in this project, the Molecular Neurogenetics Laboratory, Australian Neuromuscular Research Institute, Perth, and the Neurogenetics Research Unit, New Children s Hospital, Sydney, have identified disease genes for congenital myopathies. Prenatal diagnosis is now possible for families whose disease-causing mutation is identified. However the genetic cause of many of the congenital myopathies remains unknown. DNA and other samples have been sent to the Laboratories from around the world, making us reference centres for congenital myopathy research. Part one of the project is to study these and Australasian samples, to identify other congenital myopathy genes. This will help families who currently cannot have prenatal diagnosis. Finding the genes also increases understanding of the diseases by clarifying which proteins are involved. In part two of the project we shall study the mutated proteins, to try to unravel how the gene mutations cause the diseases. The third part of the project is to reevaluate the highly variable muscle pathology in congenital myopathies in cases where the disease gene is now known, in order to investigate genotype-phenotype correlations. Understanding the pathologic basis of the congenital myopathies will ultimately allow us to begin to think rationally about possible treatments.Read moreRead less
Magnetic Resonance Methods For Automated, Non-invasive Diagnosis Of Focal Brain Infections
Funder
National Health and Medical Research Council
Funding Amount
$483,564.00
Summary
Brain lesions caused by infections, tumours and some other diseases, often cannot be distinguished from each other clinically or by neuro-radiology examinations. A brain biopsy is usually needed to make a definite diagnosis and may cause sequelae or not be possible if the lesion is in certain areas of the brain. Magnetic resonance imaging (MRI) has increased our ability to detect brain lesions but cannot unequivocally diagnose the disease process. Magnetic resonance spectroscopic (MRS) methods r ....Brain lesions caused by infections, tumours and some other diseases, often cannot be distinguished from each other clinically or by neuro-radiology examinations. A brain biopsy is usually needed to make a definite diagnosis and may cause sequelae or not be possible if the lesion is in certain areas of the brain. Magnetic resonance imaging (MRI) has increased our ability to detect brain lesions but cannot unequivocally diagnose the disease process. Magnetic resonance spectroscopic (MRS) methods report on the chemical composition of lesions and can provide a simultaneous picture of the location of the lesion and the pathology of the disease process. Brain biopsies may therefore be avoided in a significant number of cases where drainage or decompression of lesions are not needed as part of therapy. Identification of specific fingerprints for the different diseases will provide a rapid, robust, automated diagnosis, which will expedite management decisions and improve patient outcomes. It should also be possible to monitor the efficacy of drug treatments using MRS methods. Each of these outcomes would constitute a major medical advance.Read moreRead less
Genetic Variants, Phenotypic Spectrum And Breast Cancer Risk Associated With Germline Mutations In PALB2: Identifying Female PALB2 Mutation Carriers At The Time Of Diagnosis
Funder
National Health and Medical Research Council
Funding Amount
$45,093.00
Summary
Population studies of female breast cancer (BC) show only a small proportion of familial aspects of BC can be explained by current knowledge of its causes. Women carrying PALB2 mutations who also have a strong family history of BC are of increased risk of BC. Our work will further define the risks and devise criteria to identify women most likely to carry PALB2 mutations. This will help prioritize testing, classify PALB2 variants and provide appropriate clinical management to carriers.
Deficiency of the protein dysferlin causes muscular dystrophy, an inherited degenerative disorder of skeletal muscle. Interestingly, muscle disease due to deficiency of dysferlin does not occur until early adulthood. Affected individuals are very active with normal strength until this age and then there is rapid progression of weakness. Many patients lose the ability to walk within a few years of onset. Little is known about the functional role of dysferlin in muscle, how dysferlin deficiency re ....Deficiency of the protein dysferlin causes muscular dystrophy, an inherited degenerative disorder of skeletal muscle. Interestingly, muscle disease due to deficiency of dysferlin does not occur until early adulthood. Affected individuals are very active with normal strength until this age and then there is rapid progression of weakness. Many patients lose the ability to walk within a few years of onset. Little is known about the functional role of dysferlin in muscle, how dysferlin deficiency results in muscular dystrophy, or why dysferlin-deficient muscle is functionally normal prior to the rapid onset of symptoms. Therefore, the goal of this study is to characterize the role of dysferlin in normal and diseased skeletal muscle. We will examine the consequence of dysferlin-deficiency in patient muscle biopsy samples and patient muscle cells in culture. We will assess the role of dysferlin in the fusion and formation of new muscle cells, examine the effect of dysferlin-deficiency on muscle membrane repair, and establish how normal and mutant dysferlin is made, trafficked and degraded within muscle cells. This research will have immediate applications to the diagnosis and counselling of patients with dysferlin-related disease. In addition it will provide valuable information concerning the mechanisms of disease, essential to the development of specific and successful therapies.Read moreRead less